Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL426034 | 0.84 | KMT2A (0.54) | TSHRALDH1A1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL10153819 | 0.80 | TSHR (0.61) | TSHRALDH1A1HSD17B10KMT2ASMN1; SMN2 | |
| SCHEMBL13485823 | 0.79 | TSHR (0.59) | TSHRALDH1A1HSD17B10 | |
| SCHEMBL422830 | 0.76 | TSHR (0.56) | TSHRALDH1A1HSD17B10KMT2ASMN1; SMN2 | |
| SCHEMBL4355804 | 0.75 | TSHR (0.54) | TSHRALDH1A1HSD17B10KMT2ASMN1; SMN2 | |
| SCHEMBL22252134 | 0.74 | TSHR (0.76) | TSHRALDH1A1HSD17B10KMT2ASMN1; SMN2 | |
| SCHEMBL2329775 | 0.74 | PTGS2 (0.64) | TSHRALDH1A1HSD17B10KMT2ASMN1; SMN2 | |
| SCHEMBL423265 | 0.74 | CA1 (0.57) | TSHRALDH1A1KMT2APKMMEN1 | |
| SCHEMBL17764 | 0.74 | GAA (0.59) | ALDH1A1HSD17B10KMT2ASMN1; SMN2PKM | |
| SCHEMBL19197973 | 0.73 | SMN1; SMN2 (0.69) | TSHRALDH1A1KMT2ASMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835461-B2 | Substituted 3-hydroxy-4-pyridone derivative | SHIONOGI & CO., LTD. (JP) | 2014-09-16 | — | — | US | disclosed |
| EP-2412708-A1 | SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE | Shionogi&Co., Ltd. (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-20120022255-A1 | SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022255-A1 | SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE | ENDOD1, CNBP, DPP4 | TSHR 3832/4885ALDH1A1 1167/4885HSD17B10 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.